Grace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business Update

Provided By GlobeNewswire

Last update: Feb 13, 2025

Announced Phase 3 STRIVE-ON Safety Trial Met Primary Endpoint and Provided Clinical Benefit Compared to Orally Administered Nimodipine; New Drug Application (NDA) Submission Anticipated First Half of Calendar 2025